Why choose OLM?

A diagnostic-led approach

  • At OLM Diagnostics we are acting to address the threat of antifungal resistance. We are discovering and developing a new diagnostic-led approach to tackling fungal infections. Our research and development drives our company focus; to reinforce our reputation as a trusted healthcare partner and to enhance patient health outcomes

Clinicians can have confidence in the sensitivity and specificity our tests – to correctly identify true positive and true negative cases

Our aim at OLM Diagnostics is to:

  • Create a paradigm shift in attitude towards the diagnosis of fungal infection

  • See a diagnostic-led approach become standard practice in hospitals worldwide

  • Launch a series of innovative tests that will identify fungal (and bacterial) infections accurately and quickly to support the use of appropriate antimicrobial prescribing

About OLM Diagnostics

OLM Diagnostics is a medical diagnostics company, which markets and distributes innovations in fungal and bacterial diagnostics to the healthcare sector. Our novel and reliable rapid-diagnostic tests fit seamlessly into current treatment pathways and can reduce the rate of drug resistant infections by promoting a new diagnosticled approach. This is achieved, whilst delivering clear financial and clinical benefits to hospitals, clinicians and patient care.

What are the benefits of using OLM Diagnostics?

  • Our tests are inexpensive and require no additional laboratory equipment, so offer the potential for cost savings for hospitals, from unnecessary prescriptions to higher costs associated with treating resistant infections. Some of these benefits include:
    • A reduced rate of drug resistant infections
    • Preservation of existing antifungal medication
    • Improvement to patient care through appropriate prescribing
    • Potential cost savings to the NHS and healthcare institutions
    • No extra costs or equipment required to run the diagnostic tests. Lab equipment already in place e.g. a PCR machine

  • Current diagnostic testing is poor, unreliable and time consuming. OLM Diagnostics offers an easy solution that allows clinicians to rapidly identify the exact cause of a patient’s infection

  • By reducing the over prescription of antifungal medicines, we are helping to combat the spread of resistant infections and improve patient outcomes

New rapid diagnostics would optimise treatment18


Rapid diagnostic testing
Our fungal diagnostic range



The AspDx range consists of a triple test approach and provides a comprehensive and rapid diagnostic service to aid real-time patient management25,26

  • The AspDx range offers the ability to detect Aspergillus species, aiding in rapid and comprehensive diagnosis. AspDx provides viable tools to allow clinicians to move to a diagnostic-led approach for the real-time management of invasive Aspergillus infections

  • The tests provide comprehensive and rapid diagnosis to aid real-time patient management, allowing clinicians to move to a diagnostic-led approach for the management of invasive Aspergillus


A multiplex PCR kit for the detection of Aspergillus species


Aspergillus Proximity Ligation Assay - For the early detection of Invasive Pulmonary Aspergillosis


Aspergillus Lateral- Flow Device - For the rapid detection of Invasive Pulmonary Aspergillosis


The CandDx range offers the ability to detect Candida species, aiding the clinician in a more accurate diagnosis and treatment approach for Candida infections


qPCR kit for the detection of clinically relevant Candida species


qPCR kit for the detection of Candida auris


PneumDx offers the ability to detect Pneumocystis jiroveciii, a common cause of pneumonia and other respiratory infections, in individuals with impaired immune systems, particularly people with HIV/AIDS


qPCR kit for the detection of Pneumocystis jirovecii

Building the case for an Antifungal Stewardship Programme (AFS)

  • A change in mindset is required among clinicians to improve antifungal use across the globe27

  • AFS programmes go some way towards addressing the issue of overprescribing of antifungals18
    • AFS encourage a coordinated programme to promote the appropriate use of antifungals to improve patient outcomes, reduce resistance, reduce costs and decrease the spread of infections (See diagram on next page)

Several recent studies have highlighted the importance of AFS in hospitals:

  • In one study, 18 months before and after the implementation of an AFS, it was observed inappropriate prescriptions for candidiasis fell from 71% to 24%28

  • Following the implementation of a 7 year AFS in a large tertiary hospital, antifungal costs went from $3.7 million to $1.3 million by the end of the programme29

  • Studies have also shown; standardised PCR methodologies can be accurately used to screen aspergillus patients30,31



  1. Brown GD et al. Sci Transl Med 2012;4(165): 165rv13.
  2. Rüping MJ et al. Drugs 2008;68(14): 1941-62.
  3. Schmiedel Y et al. Swiss Med Wkly 2016;146: w14281.
  4. Wisplinghoff et al. Clin Infect Dis 2004;39: 309-17.
  5. Kollef M et al. Clin Infect Dis 2012;54: 1739-1746.
  6. Hadley S et al. Crit Care Med 2002;30(8): 1808-14.
  7. Leroy O et al. Crit Care Med 2009;37(5): 1612-8.
  8. Guzman JA et al. Clin Med Res 2011;3: 65-71.
  9. Charles PE et al. Intensive Care Med 2003;29(12): 2162-9.
  10. Nolla-Salas J et al. Intensive Care Med 1997;23(1): 23-30.
  11. Bougnoux ME et al. Intensive Care Med 2008;34(2): 292-9.
  12. Alexander BD et al. Clin Infect Dis 2014;58(5): 754.
  13. Biggest Threats - Antibiotic/Antimicrobial Resistance - CDC. Web: https://www.cdc.gov/drugresistance/biggest_threats.html (Last accessed: March 2017).
  14. Kontoyiannis DP et al. Clin Infect Dis 2010;50: 1091-100.
  15. Falcone M et al. Med Mycol 2011;49(4): 406-413.
  16. Fairlamb AH et al. Nat Microbiol 2016;1(7): e16092.
  17. Agrawal S et al. J Antimicrob Chemother 2016;71 Suppl 2: ii37-ii42.
  18. O’Neill J. Tackling drug-resistant infections globally: Final report and recommendations. The review on antimicrobial resistance; London: HM Government and the Wellcome Trust; 2016.
  19. Valerio M et al. J Antimicrob Chemother 2014;69: 1993-9.
  20. Ceesay MM et al. J Antimicrob Chemother 2015;70: 1175-1181.
  21. Roberts RR et al. Clin Infect Dis 2009;49(8): 1175-84.
  22. Arendrup MC et al. Bone Marrow Transplant 2012;47: 1030-45.
  23. Arendrup MC et al. Clin Microbial Infect 2014;20 (Suppl. 6): 42-48.
  24. Barnes R et al. Clin Thera 2015;37(6): 1317-1328.e2.
  25. Hoenigl M et al. J Clin Microbiol 2014;52(6): 2039-2045.
  26. White PL et al. J Clin Microbiol 2013;51(5): 1510-1516.
  27. Bassetti M et al. J Antimicrob Chemother 2016;71 (suppl_2): ii13-ii22.
  28. Apisarnthanarak A et al. Infect Control Hosp Epidemiol 2012;31: 722-7.
  29. Standiford HC et al. Infect Control Hosp Epidemiol 2012;33: 338-45.
  30. Leeflang MM et al. Cochrane Database Syst Rev 2008;4: CD0073944.
  31. Cruciani M et al. Cochrane Database Syst Rev 2015;10: CD009551.